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Purpose: Healthy Corneal endothelium is essential for corneal clarity. Treatment of 
defective corneal endothelial function often requires corneal transplant. Gene therapy 
is an attractive approach to treat/cure corneal endothelial diseases. We evaluated gene 
transfer efficacy of AAV and GNP vectors for delivering therapeutic genes into 
human corneal endothelial cells. 
 
Methods: Cultures of HPV16-E6/E7 transformed human corneal endothelial cells 
were incubated with AAV2/6, AAV2/8, AAV2/9 or GNP vector expressing reporter 
gene for 6 hours. Transfection efficiency was quantified with cytochemical or 
immuno staining and real-time polymerase chain reactions techniques. Commecial 
kits were used to prepare RNA and cDNA. Cellular viability was tested using Trypan 
blue assay.  
 
Results: Immunocytochemical quantification of GFP-positive cells in cultures 
revealed 30% transgene delivery into endothelial cells with gold nanoparticles. The 
three tested AAV serotypes showed up to 2% endothelial transduction. The AAV6 
was found most efficacious among 3 AAVs. These findings were complimented by 
the Real-time PCR data. AAV vectors did not alter cellular viability whereas notable 
decrease in cellular viability was noted with GNP vector.  
 
Conclusions: AAV6 and GNP vectors are efficient at introducing therapeutic genes 
into human corneal endothelial cells. More studies are required to define dose and 
safety of tested vectors for corneal endothelial gene therapy.  
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